Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Liuwei Anshen is a Traditional Chinese Medicine (TCM) capsule formulation developed by the Oriental Hospital of Beijing University of Traditional Chinese Medicine. It is primarily indicated for the treatment of chronic insomnia, specifically targeting the "yin deficiency and fire hyperactivity with phlegm" syndrome. The therapeutic mechanism of Liuwei Anshen is currently being investigated through the lens of the inflammation-mediated microbial gut-brain axis, suggesting that the formula may exert its sedative and sleep-promoting effects by modulating gut microbiota composition and systemic inflammatory pathways. As a multi-component herbal preparation, it represents a holistic approach to managing sleep disorders within the framework of integrative medicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on liuwei anshen.